Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look

Milena Bruzzone, Lazzaro Repetto, Silvana Chiara, Elisabetta Campora, Pier Franco Conte, Marco Orsatti, Vito Vitale, Alessandra Rubagotti, Riccardo Rosso

Research output: Contribution to journalArticle

Abstract

The management of patients with epithelial ovarian cancer with no or minimal residual disease at second-look laparotomy after aggressive surgery and platinum-based chemotherapy has not been definitively established. We report the results of a randomized study comparing three more courses of the same chemotherapy inducing the response (21 patients) with whole-abdomen radiotherapy (20 patients). Thirty-eight patients responded to first-line chemotherapy and three had stabilization of disease. In eight patients tumor debulking was performed at second-look laparotomy. No severe toxic effects were noted in both arms. Bowel obstruction occurred in one patient treated with radiotherapy. At a median follow-up of 22 months, 11 of 20 patients in the radiotherapy arm and 6 of 21 in the chemotherapy arm progressed and 9 and 3 patients died, respectively. Although the number of randomized patients is small we stopped the trial because of the survival and progression-free survival advantage of chemotherapy-treated patients.

Original languageEnglish
Pages (from-to)392-395
Number of pages4
JournalGynecologic Oncology
Volume38
Issue number3
DOIs
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look'. Together they form a unique fingerprint.

  • Cite this